TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30912838

Group type: EXPERIMENTAL
Intervention: Intramyocardial injections of 150 million allogeneic mesenchymal precursor cells (MPCs)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Cryoprotective medium (sham treatment)
Number of subjects: 159
Study: 29705935

Group type: EXPERIMENTAL
Intervention: 6-week behavioral skills plus positive parenting and peer monitoring intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: General health comparison program
Number of subjects: 89
Study: 27107519

Group type: EXPERIMENTAL
Intervention: Orem's self-care nursing model (four 30-45 minutes training sessions)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study: 24255129

Group type: EXPERIMENTAL
Intervention: Serelaxin (30 µg/kg/day 20‐h infusion and 4‐h post‐infusion period)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 22850511

Group type: EXPERIMENTAL
Intervention: VP20621 (10^4, 10^6, or 10^8 spores)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VP20621 (10^8 spores twice a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VP20621 (10^4, 10^6, or 10^8 spores daily) after vancomycin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VP20621
Number of subjects: 0
Study: 20492512

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a 180 microg/week (PEG)
Number of subjects: 105

Group type: COMPARATOR
Intervention: alpha‐tocopherol 1000 mg/day (TOCO)
Number of subjects: 105
Study: 18606249

Group type: EXPERIMENTAL
Intervention: Daily assessment (daily diaries)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard weekly clinic assessment
Number of subjects: 78
Study: 16020959

Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg orally 3 times daily
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 12449159

Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 546

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 546
Study: 11120419

Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose 4.35 +/- 1.7 mg/day)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Olanzapine (mean dose 10.56 +/- 4.9 mg/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Haloperidol (mean dose 10.01 +/- 6.1 mg/day)
Number of subjects: 76
Study: 8898512

Group type: EXPERIMENTAL
Intervention: European version (ET)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Canadian version (CT)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Direct measurement (DM) via standard open circuit spirometry
Number of subjects: 500
Study: 1649874

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of two rotavirus vaccine strains (VP7 serotypes 1 and 2)
Number of subjects: 0
Study: 6360401

Group type: EXPERIMENTAL
Intervention: Mefloquine (1000 mg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (1500 mg + 75 mg pyrimethamine)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study: 30893284

Group type: EXPERIMENTAL
Intervention: LMA Fastrach‐flexible bronchoscopy‐guided technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Video laryngoscopy‐guided intubation
Number of subjects: 40
Study: 29920594

Group type: COMPARATOR
Intervention: 0 μg/d vitamin D3
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 10 μg/d vitamin D3
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 20 μg/d vitamin D3
Number of subjects: 110
Study: 27628763

Group type: EXPERIMENTAL
Intervention: Warfarin (low-dose, short-term use)
Number of subjects: 78615

Group type: EXPERIMENTAL
Intervention: Warfarin (low-dose)
Number of subjects: 78615

Group type: EXPERIMENTAL
Intervention: Warfarin (long-term, high-dose use)
Number of subjects: 78615

Group type: COMPARATOR
Intervention: Other anticoagulants
Number of subjects: 78615
Study: 24979398

Group type: EXPERIMENTAL
Intervention: AM‐111 0.4 mg/ml
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 22024564

Group type: EXPERIMENTAL
Intervention: Milk product enriched with soy isoflavones (50 mg/day)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 99
Study: 19901111

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (docetaxel/doxorubicin/cyclophosphamide (TAC) or two cycles of TAC followed by four cycles of vinorelbine/capecitabine)
Number of subjects: 2064

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 2064
Study: 17660130

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Epidural Analgesia (PCEA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Intermittent Opiate Regimen (IOR)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 92
Study: 16189745

Group type: EXPERIMENTAL
Intervention: Hypericum extract WS(R) 5570/5572
Number of subjects: 594

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study: 12161224

Group type: EXPERIMENTAL
Intervention: Rotational spin coronary angiography
Number of subjects: 15
Study: 10433621

Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid (13‐cis‐RA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 8535552

Group type: EXPERIMENTAL
Intervention: Felodipine 10-20 mg daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Metoprolol 100-200 mg daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination of felodipine 10-20 mg plus metoprolol 100 mg daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2199180

Group type: EXPERIMENTAL
Intervention: 100 I.U. calcitonin subcutaneously every second evening
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 100 I.U. calcitonin subcutaneously every evening
Number of subjects: 59

Group type: COMPARATOR
Intervention: No specific medication
Number of subjects: 59
Study: 872364

Group type: EXPERIMENTAL
Intervention: Pyridine-extracted alum-precipitated grass pollen vaccine (Alavac P)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Glutaraldehyde-modified pollen-tyrosine vaccine (Pollinex)
Number of subjects: 19
Study: 31752802

Group type: EXPERIMENTAL
Intervention: Tuberculosis treatment
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Current alcohol consumption
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Tobacco product use, current alcohol consumption, family history of diabetes, and stress level
Number of subjects: 320
Study: 28506378

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (contacting primary care prescribers by phone and fax to obtain a prescription for an appropriate statin)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 420
Study: 24335848

Group type: EXPERIMENTAL
Intervention: candesartan 16 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: propranolol 160 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study: 23511692

Group type: EXPERIMENTAL
Intervention: 1 g acetaminophen
Number of subjects: 53

Group type: COMPARATOR
Intervention: 1 g dextrose (placebo)
Number of subjects: 53
Study: 20847992

Group type: EXPERIMENTAL
Intervention: Cosci technique
Number of subjects: 15

Group type: COMPARATOR
Intervention: Summers technique
Number of subjects: 15
Study: 19075138

Group type: EXPERIMENTAL
Intervention: Dapsone gel, 5%
Number of subjects: 64

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 64

Group type: COMPARATOR
Intervention: Dapsone gel, 5% and Vehicle gel
Number of subjects: 64
Study: 16550976

Group type: EXPERIMENTAL
Intervention: IV tramadol
Number of subjects: 44

Group type: COMPARATOR
Intervention: IV lornoxicam
Number of subjects: 44
Study: 14599636

Group type: EXPERIMENTAL
Intervention: Gene therapy for severe combined immunodeficiency disorder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy for cystic fibrosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy for coronary artery disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy for peripheral arterial disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy for hemophilia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy (general)
Number of subjects: 0
Study: 10920683

Group type: EXPERIMENTAL
Intervention: Nutritional Support Team (NST)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-NST
Number of subjects: 96
Study: 9188878

Group type: EXPERIMENTAL
Intervention: Calcitriol (3 micrograms/g) ointment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcipotriol (50 micrograms/g) ointment
Number of subjects: 24
Study: 7925201

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (3 x ED90)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vecuronium (3 x ED90)
Number of subjects: 0
Study: 3194074

Group type: EXPERIMENTAL
Intervention: Cefoxitin 1 g intravenously at induction of anaesthesia
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g intravenously at induction of anaesthesia
Number of subjects: 240
Study: 31438861

Group type: EXPERIMENTAL
Intervention: Disposcope endoscope-guided NTI
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fibreoptic bronchoscopy-guided NTI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 28099359

Group type: EXPERIMENTAL
Intervention: Xenon-enhanced CT using a single-breath-hold technique
Number of subjects: 26
Study: 27738739

Group type: EXPERIMENTAL
Intervention: Standardized perioperative behavioral/pelvic floor exercise intervention plus midurethral sling
Number of subjects: 210

Group type: COMPARATOR
Intervention: Midurethral sling alone
Number of subjects: 210
Study: 24206459

Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (20 mg daily)
Number of subjects: 2185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study: 21889878

Group type: EXPERIMENTAL
Intervention: Lurasidone 120 mg once daily
Number of subjects: 301

Group type: COMPARATOR
Intervention: Ziprasidone 80 mg BID
Number of subjects: 301
Study: 18927168

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET) group
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 17926618

Group type: EXPERIMENTAL
Intervention: Eye acupuncture
Number of subjects: 180

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Bucinnazine
Number of subjects: 180
Study: 15521869

Group type: EXPERIMENTAL
Intervention: Endometrial polyps
Number of subjects: 78

Group type: COMPARATOR
Intervention: Normal endometrium
Number of subjects: 78
Study: 11172164

Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 or 5.0 mg daily)
Number of subjects: 9331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9331
Study: 8968227

Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic adrenalectomy (TLPA)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic approach (RLPA)
Number of subjects: 9
Study: 1610635

Group type: EXPERIMENTAL
Intervention: Anaesthesia with enflurane in nitrous oxide with spontaneous ventilation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anaesthesia with isoflurane in nitrous oxide with spontaneous ventilation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anaesthesia with enflurane in nitrous oxide with controlled ventilation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anaesthesia with isoflurane in nitrous oxide with controlled ventilation
Number of subjects: 40
Study: 3918510

Group type: EXPERIMENTAL
Intervention: Lentinan in combination with chemotherapeutic agents (5FU + mitomycin C or tegafur)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lentinan in combination with tegafur for gastric cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lentinan in combination with tegafur for colorectal cancer
Number of subjects: 0
Study: 30866888

Group type: EXPERIMENTAL
Intervention: PMT biscuits and nutrition education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrition education only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PMT biscuits only
Number of subjects: 0
Study: 30062572

Group type: EXPERIMENTAL
Intervention: 6-month weight loss intervention (n=93)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care (n=58)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 6-month weight loss intervention (n=93) among women with stage 0/I
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care (n=58) among women with stage 0/I
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Weight loss intervention in women with stage II/III
Number of subjects: 151
Study: 27684867

Group type: EXPERIMENTAL
Intervention: Spontaneously removable biliary stent drainage
Number of subjects: 47

Group type: COMPARATOR
Intervention: T-tube drainage
Number of subjects: 47
Study: 24650858

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fibromyalgia Education (FE)
Number of subjects: 100
Study: 22429658

Group type: EXPERIMENTAL
Intervention: Age-specific echocardiographic criteria for diastolic LV dysfunction
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: Diastolic dysfunction groups 1 (impaired relaxation), 2 (possible elevated LV filling pressure), and 3 (elevated E/e' and abnormally low E/A)
Number of subjects: 1258
Study: 19443680

Group type: EXPERIMENTAL
Intervention: Telavancin 10 mg/kg + Aztreonam 2 g
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Telavancin 10 mg/kg + Piperacillin/Tazobactam 4.5 g
Number of subjects: 23

Group type: COMPARATOR
Intervention: Telavancin 10 mg/kg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Aztreonam 2 g
Number of subjects: 23

Group type: COMPARATOR
Intervention: Piperacillin/Tazobactam 4.5 g
Number of subjects: 23
Study: 17877851

Group type: EXPERIMENTAL
Intervention: Personality measures (authoritarianism, personal need for structure, ethnocentrism, social dominance orientation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-group identification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social dominance orientation (SDO)
Number of subjects: 0
Study: 15051633

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 70

Group type: COMPARATOR
Intervention: Unstable angina patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 70
Study: 11270009

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5 L min‐1 for at least 2 h)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Isoflurane (0.5 L min‐1 for at least 2 h)
Number of subjects: 76
Study: 9698963

Group type: EXPERIMENTAL
Intervention: TIVA (propofol and remifentanil)
Number of subjects: 50

Group type: COMPARATOR
Intervention: DN (desflurane-N2O)
Number of subjects: 50
Study: 10512080

Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg/day
Number of subjects: 250

Group type: COMPARATOR
Intervention: Amitriptyline 25-75 mg/day
Number of subjects: 250
Study: 2376155

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP, 500 micrograms twice daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 16
Study: 216235

Group type: EXPERIMENTAL
Intervention: 25 mg oxazepam
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 31418140

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg daily for 48 weeks
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 188
Study: 27899322

Group type: EXPERIMENTAL
Intervention: Ampicillin and/or sulbactam administered 1 hour before ESD and every 8 hours twice more (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline solution without antibiotics (group 2)
Number of subjects: 100
Study: 26414759

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) plus usual care (UC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 158
Study: 23642010

Group type: EXPERIMENTAL
Intervention: Web 1.0 intervention (access to an existing physical activity website with limited interactivity)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Web 2.0 intervention (access to a website featuring Web 2.0 content, including social networking, blogs, and virtual walking groups)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control group (received a logbook to record their steps)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: All groups (including Web 1.0, Web 2.0, and Control)
Number of subjects: 504
Study: 21315749

Group type: EXPERIMENTAL
Intervention: Increased activation following threatening stimuli in the left temporo‐parietal junction and right extrastriate body area correlating with more social inhibition traits.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Negative correlation between negative affectivity and activation of the amygdala, fusiform gyrus, insula, and hippocampus.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Positive correlation with social inhibition in the orbitofrontal cortex, superior temporal sulcus, inferior frontal gyrus (Brodmann area 45), and temporal pole.
Number of subjects: 26
Study: 19826188

Group type: EXPERIMENTAL
Intervention: Green tea catechins (GTC) - 670 mg per day (6 capsules)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High dietary GTC (5 g GTC/kg) in male rats
Number of subjects: 17

Group type: COMPARATOR
Intervention: Lower dietary GTC (0, 0.05, 0.5, 1 g GTC/kg) in male rats
Number of subjects: 17
Study: 16962480

Group type: EXPERIMENTAL
Intervention: BT563
Number of subjects: 40

Group type: COMPARATOR
Intervention: ATG
Number of subjects: 40
Study: 15458566

Group type: EXPERIMENTAL
Intervention: 4 mls of nebulized isotonic saline using an efficient nebulizer (active group n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 4 mls of nebulized saline using an inefficient nebulizer (placebo group n = 20)
Number of subjects: 40
Study: 11372037

Group type: EXPERIMENTAL
Intervention: TFPI (0.2 mg/kg/h after a bolus of 0.05 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9236484

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (0.5, 1, or 2 g/kg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo solution (1% albumin)
Number of subjects: 99
Study: 8106652

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 3308970

Group type: EXPERIMENTAL
Intervention: Test dentifrice containing zinc citrate and Triclosan for 6 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo dentifrice for 6 months
Number of subjects: 101
Study: 29874180

Group type: EXPERIMENTAL
Intervention: Genetically predicted ETP
Number of subjects: 195458

Group type: EXPERIMENTAL
Intervention: Genetically predicted vWF
Number of subjects: 195458

Group type: EXPERIMENTAL
Intervention: Genetically predicted FVIII
Number of subjects: 195458

Group type: EXPERIMENTAL
Intervention: Genetically predicted d‐dimer
Number of subjects: 195458

Group type: EXPERIMENTAL
Intervention: Genetically predicted tPA
Number of subjects: 195458

Group type: EXPERIMENTAL
Intervention: Genetically predicted PAI-1
Number of subjects: 195458
Study: 28611206

Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein isolation (CPVI) alone (n=59)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Circumferential pulmonary vein isolation (CPVI) plus linear ablation (CPVI+Line; n=54)
Number of subjects: 113
Study: 26111066

Group type: EXPERIMENTAL
Intervention: TF-CBT (n = 131)
Number of subjects: 257

Group type: COMPARATOR
Intervention: TAU (n = 126)
Number of subjects: 257
Study: 23611874

Group type: EXPERIMENTAL
Intervention: Tailored mobile telephone text messages (SMS) after discharge from psychiatric hospital, frequency and content chosen by patients, for 12 months.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care at the discretion of the team (psychiatry and nursing).
Number of subjects: 45
Study: 21092221

Group type: EXPERIMENTAL
Intervention: NVP (5 g) added to cornflakes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NVP (5 g) added to rice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NVP (5 g) added to yogurt
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NVP (5 g) added to turkey dinner
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NVP (2.5 g) added to granola
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NVP (5 g) added to granola
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no NVP) granola
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NVP (5 g) added to various foods
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NVP (5 g) in general
Number of subjects: 10
Study: 18691987

Group type: EXPERIMENTAL
Intervention: Rifampicin 450 mg once daily for 6 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15929958

Group type: EXPERIMENTAL
Intervention: Standard therapy plus as-needed ambulatory oxygen
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard therapy plus ambulatory compressed air
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard therapy (home oxygen therapy with an oxygen concentrator only)
Number of subjects: 24
Study: 12912865

Group type: EXPERIMENTAL
Intervention: Topical capsaicin (0.006%)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (menthol 1%)
Number of subjects: 44
Study: 10593470

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA), n=30
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA), n=30
Number of subjects: 60
Study: 8887597

Group type: EXPERIMENTAL
Intervention: Breathing 60% O2 with added external dead space (O2VD)
Number of subjects: 7